Second-generation kinase inhibitors

By Klebl Bert M   Müller Gerhard  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 5, 2005-10 ,pp. : 975-993

Informa Healthcare

Access to resources Recommend Favorite

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By Soverini Simona   De Benedittis Caterina   Papayannidis Cristina   Paolini Stefania   Venturi Claudia   Iacobucci Ilaria   Luppi Mario   Bresciani Paola   Salvucci Marzia   Russo Domenico   Sica Simona   Orlandi Ester   Intermesoli Tamara   Gozzini Antonella   Bonifacio Massimiliano   Rigolin Gian Matteo   Pane Fabrizio   Baccarani Michele   Cavo Michele   Martinelli Giovanni  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

Blackwell Publishing

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 391-401

Bentham Science Publishers

Access to resources Recommend Favorite

Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy

By  

Current Medicinal Chemistry, Vol. 23, Iss. 29, 2016-10 ,pp. : 3343-3359

Bentham Science Publishers

Access to resources Recommend Favorite

Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 13, 2016-05 ,pp. : 1452-1462

Bentham Science Publishers

Access to resources Recommend Favorite